Previous 10 | Next 10 |
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had another lackluster week, opening last Tuesday (September 3) after the long weekend at 3,219.88 points before settling at 3,229.42 points as of 1:32 p.m. EDT on Friday (September 6). Over the short trading week, the US Food and Drug Admin...
Gainers: OpGen (NASDAQ: OPGN ) +79% . Marinus Pharmaceuticals (NASDAQ: MRNS ) +35% . Top Ships (NASDAQ: TOPS ) +25% . Natuzzi S.p.A. (NYSE: NTZ ) +23% . Mereo BioPharma Group (NASDAQ: MREO ) +23% . Ovid Therapeutics (NASDAQ: OVID ) +19% . Owens & Minor (NYSE: OMI ) +19% . ...
Correvio Pharma (NASDAQ: CORV ) initiated with Overweight rating and $6 (193% upside) price target at Cantor Fitzgerald. More news on: Correvio Pharma Corp., InMode Ltd., MeiraGTx Holdings plc, Healthcare stocks news, Stocks on the move, , Read more ...
Marinus Pharmaceuticals (NASDAQ: MRNS ): Q2 GAAP EPS of -$0.24 in-line. More news on: Marinus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Top-line Phase 2 refractory status epilepticus (RSE) data on-track for Q3 2019 Scott Braunstein, MD appointed as CEO Nicole Vitullo appointed as Chairman of the Board RADNOR, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutica...
Gainers: DelMar Pharmaceuticals (NASDAQ: DMPI ) +39%. SigmaTron International (NASDAQ: SGMA ) +22% . Nuvectra Corporation (NASDAQ: NVTR ) +20% . Teradyne (NASDAQ: TER ) +18% . Manhattan Associates (NASDAQ: MANH ) +18% . Snap (NYSE: SNAP ) +16% . Acasti Pharma (NASDAQ: ACS...
Marinus ( MRNS ) has been a controversial stock for some time, as the company looked to challenge Sage ’s ( SAGE ) Zulresso with its “similar but different” compound ganaxolone, and questions about the efficacy of the drug and its chronic clinical timeline slips dogged ...
Introduction Unfortunately for Marinus Pharmaceuticals ( MRNS ) investors, the writing has been on the wall for awhile in regards to its only asset, ganaxolone. Management, after delays and lowered expectations, revealed interim phase 2 postpartum depression [PPD] data in December 2018. A...
Gainers : Therapix Biosciences (NASDAQ: TRPX ) +45% . Chiasma (NASDAQ: CHMA ) +31% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +24% . Hoth Therapeutics (NASDAQ: HOTH ) +20% . Torchlight Energy Resources (NASDAQ: TRCH ) +17% . Realogy Holdings (NYSE: RLGY ) +16% . ClearSign Combustion...
Marinus Pharmaceuticals (NASDAQ: MRNS ) -66% on disappointing ganaxolone data . More news on: Marinus Pharmaceuticals, Inc., LSC Communications, Inc., ACADIA Pharmaceuticals Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...